Ophthalmic nano-bioconjugates: critical challenges and technological advances

Area of Science:

• Ophthalmology and Pharmaceutical Sciences
• Biomedical Engineering
• Nanotechnology

Background:

• Ophthalmic diseases can lead to irreversible vision loss and blindness.
• Effective topical and systemic treatments are crucial for sight-threatening ocular conditions.
• Conventional ophthalmic drug delivery faces significant anatomical and physiological challenges, limiting bioavailability.

Purpose of the Study:

• To review novel nanocarrier-based drug delivery systems for ophthalmic applications.
• To highlight advancements in biocompatible, safe, and therapeutic nanocarrier designs.
• To discuss the potential of nanocarriers in overcoming ocular drug delivery barriers.

Main Methods:

• Literature review of recent advancements in nanocarrier technology for ocular drug delivery.
• Analysis of nanocarrier design modifications to enhance ocular residence time and permeability.
• Examination of patented developments and clinical trial data related to ocular nanomedicine.

Main Results:

• Novel nanocarrier designs demonstrate potential for improved drug bioavailability in the eye.
• Nanocarriers can enhance drug penetration across the cornea and increase residence time.
• Modified nanocarriers show promise for treating both anterior and posterior segment eye disorders.

Conclusions:

• Nanocarrier-based systems represent a promising strategy for advanced ocular drug delivery.
• Biocompatible and therapeutically effective nanocarriers can overcome limitations of conventional treatments.
• Further research and clinical validation are supported by existing technologies and trial data.